Are prolactin levels efficient in predicting a pituitary lesion in patients with hyperprolactinemia?
Hyperprolactinemia
Pituitary lesion
Prolactin
Sellar mass
Serial sampling
Stalk-effect
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
09 Jan 2024
09 Jan 2024
Historique:
received:
16
11
2023
accepted:
25
12
2023
medline:
9
1
2024
pubmed:
9
1
2024
entrez:
9
1
2024
Statut:
aheadofprint
Résumé
Data regarding the presence of a prolactin (PRL) threshold above which a pituitary magnetic resonance imaging (MRI) is mandatory in patients with hyperprolactinemia (hyperPRL) are controversial and derived primarily from studies focused on female populations. Aim of our study was to evaluate in a cohort of patients of both sexes with confirmed hyperPRL, the possible correlation between PRL values and the presence of pituitary abnormalities. We retrospectively analyzed data from patients who underwent serial PRL sampling at our Division between January 2015 and December 2022. Patients diagnosed with monomeric hyperPRL at serial sampling and with subsequent contrast-enhanced MRI results available for the pituitary region were included in the study. Exclusion criteria were prior pituitary disease, severe renal insufficiency, liver cirrhosis, uncompensated primary hypothyroidism and ongoing therapy with hyperprolactinemic drugs. Physiological causes of hyperPRL were also ruled out. Out of the 1253 patients who underwent serial PRL sampling, 139 patients (101 women and 38 men) met the inclusion criteria: 106 (76.3%) patients had some form of pituitary disease, with microlesions observed in 69.8%, macrolesions in 25.5% and other findings in 4.7% of subjects. PRL values showed a modest accuracy in predicting the presence of a pituitary abnormality and the best cut-offs identified were >25 µg/L (AUC 0.767, p = 0.003) and >44.2 µg/L (AUC 0.697, p < 0.001) in men and women, respectively; however, if only patients with PRL values > 500 µg/L were excluded from the analysis, as they were already supposed to harbor a macroprolactinoma, PRL levels were not able to predict the presence of a macrolesion neither in men nor women. Given the high prevalence of pituitary abnormalities in patients of both sexes with hyperPRL at serial sampling, performing a pituitary imaging in all cases of hyperPRL, even if mild, appears to be a cautious choice.
Identifiants
pubmed: 38194218
doi: 10.1007/s12020-023-03678-z
pii: 10.1007/s12020-023-03678-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
B.M. Biller, A. Luciano, P.G. Crosignani, M. Molitch, D. Olive et al. Guidelines for the diagnosis and treatment of hyperprolactinemia. J. Reprod. Med. 44, 1075–1084 (1999)
pubmed: 10649814
A. Majumdar, N.S. Mangal, Hyperprolactinemia. J. Hum. Reprod. Sci. 6, 168–175 (2013)
doi: 10.4103/0974-1208.121400
pubmed: 24347930
pmcid: 3853872
I. Samperi, K. Lithgow, N. Karavitaki, Hyperprolactinaemia. J. Clin. Med. 8, 2203 (2019)
doi: 10.3390/jcm8122203
pubmed: 31847209
pmcid: 6947286
M.E. Freeman, B. Kanyicska, A. Lerant, G. Nagy, Prolactin: structure, function, and regulation of secretion. Physiol. Rev. 80, 1523–1631 (2000)
doi: 10.1152/physrev.2000.80.4.1523
pubmed: 11015620
S. Melmed, F.F. Casanueva, A.R. Hoffman, D.L. Kleinberg, V.M. Montori et al. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 273–288 (2011)
doi: 10.1210/jc.2010-1692
pubmed: 21296991
M.B. Whyte, S. Pramodh, L. Srikugan, J.A. Gilbert, J.P. Miell et al. Importance of cannulated prolactin test in the definition of hyperprolactinaemia. Pituitary 18, 319–325 (2015)
doi: 10.1007/s11102-014-0576-7
pubmed: 24879500
A. Colao, Pituitary tumours: the prolactinoma. Best. Pr. Res Clin. Endocrinol. Metab. 23, 575–596 (2009)
doi: 10.1016/j.beem.2009.05.003
L. Vilar, M.C. Freitas, L.A. Naves, L.A. Casulari, M. Azevedo et al. Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients. J. Endocrinol. Invest 31, 436–444 (2008)
doi: 10.1007/BF03346388
pubmed: 18560262
N. Karavitaki, G. Thanabalasingham, H.C.A. Shore, R. Trifanescu, O. Ansorge et al. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin. Endocrinol. (Oxf.) 65, 524–529 (2006)
doi: 10.1111/j.1365-2265.2006.02627.x
pubmed: 16984247
T. Rand, E. Kink, M. Sator, B. Schneider, J. Huber et al. MRI of microadenomas in patients with hyperprolactinaemia. Neuroradiology 38, 744–746 (1996)
doi: 10.1007/s002340050340
pubmed: 8957798
F.F. Casanueva, M.E. Molitch, J.A. Schlechte, R. Abs, V. Bonert et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin. Endocrinol. (Oxf.) 65, 265–273 (2006)
doi: 10.1111/j.1365-2265.2006.02562.x
pubmed: 16886971
Petersenn S., Fleseriu M., Casanueva F.F., Giustina A., Biermasz N., et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat. Rev. Endocrinol. 1–19 (2023)
A. Bayrak, P. Saadat, E. Mor, L. Chong, R.J. Paulson et al. Pituitary imaging is indicated for the evaluation of hyperprolactinemia. Fertil. Steril. 84, 181–185 (2005)
doi: 10.1016/j.fertnstert.2005.01.102
pubmed: 16009175
Z. Godinjak, E. Idrizbegovic, A. Rama, Correlation between hyperprolactinemia, MRI of hypophysis and clinical presentation in infertile patients. Med. Arch. 67, 22–24 (2013)
doi: 10.5455/medarh.2013.67.22-24
pubmed: 23678832
I. Souter, L.M. Baltagi, T.L. Toth, J.C. Petrozza, Prevalence of hyperprolactinemia and abnormal magnetic resonance imaging findings in a population with infertility. Fertil. Steril. 94, 1159–1162 (2010)
doi: 10.1016/j.fertnstert.2009.12.017
pubmed: 20116788
S.H. Hou, S. Grossman, M.E. Molitch, Hyperprolactinemia in patients with renal insufficiency and chronic renal failure requiring hemodialysis or chronic ambulatory peritoneal dialysis. Am. J. Kidney Dis. 6, 245–249 (1985)
doi: 10.1016/S0272-6386(85)80181-5
pubmed: 4050782
H.J. Teede, M.L. Misso, M.F. Costello, A. Dokras, J. Laven et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum. Reprod. 33, 1602–1618 (2018)
doi: 10.1093/humrep/dey256
pubmed: 30052961
pmcid: 6112576
G. Beccuti, F. Guaraldi, G. Natta, V. Cambria, N. Prencipe et al. Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study. J. Endocrinol. Invest 44, 1699–1706 (2021)
doi: 10.1007/s40618-020-01478-0
pubmed: 33314003
P. Chanson, D. Maiter, The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new. Best. Pr. Res Clin. Endocrinol. Metab. 33, 101290 (2019)
doi: 10.1016/j.beem.2019.101290
I. Shimon, Y. Rudman, Y. Manisterski, A. Gorshtein, H. Masri et al. True hyperprolactinemia in men without visible pituitary adenoma. Endocrine 72, 809–813 (2021)
doi: 10.1007/s12020-021-02624-1
pubmed: 33566310
C. Di Somma, E. Scarano, G. de Alteriis, L. Barrea, E. Riccio et al. Is there any gender difference in epidemiology, clinical presentation and co-morbidities of non-functioning pituitary adenomas? A prospective survey of a National Referral Center and review of the literature. J. Endocrinol. Invest 44, 957–968 (2021)
doi: 10.1007/s40618-020-01379-2
pubmed: 32894472
C. Delcour, G. Robin, J. Young, D. Dewailly, PCOS and Hyperprolactinemia: what do we know in 2019? Clin. Med Insights Reprod. Health 13, 1179558119871921 (2019)
doi: 10.1177/1179558119871921
pubmed: 31523136
pmcid: 6734626